To include your compound in the COVID-19 Resource Center, submit it here.

Gilead reports weak HCV sales, provides update on Yescarta launch

Late Thursday, Gilead Sciences Inc. (NASDAQ:GILD) announced 3Q17 earnings that included weaker than expected HCV sales. The company's figure of $2.20 billion was less than the Street's $2.26

Read the full 287 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE